Loading
Genecast's methylation blood test for seven cancers found about two in three cancers in a laboratory set at 98 to 100% specificity, and about half of early-stage cancers.
Xiong and colleagues (Kunming Medical University with Genecast Biotechnology, Wuxi) ran enzymatic-conversion targeted methylation sequencing of plasma from 500 healthy controls and 733 patients with breast, colorectal, oesophageal, gastric, liver, lung or pancreatic cancer, plus an independent cohort of 143 controls and 179 liver or stomach cancer patients. The model used 57 diagnostic markers and 873 origin markers. Specificity was 100% in testing and 98.6% in independent validation; overall sensitivity was 67.3% and 55.9%; early-stage (I and II) sensitivity was 45.7% in testing. Among correctly detected cancers the top predicted origin was right in 77.7% (testing) and 76.0% (independent validation). The authors state that real-world performance needs a much larger prospective cohort.
A company development study with known cancers; the authors themselves say it has to be tested prospectively.
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/